Roivant Sciences is projected to report a Q2 2026 revenue of approximately $2.00 million and a consensus EPS loss of -$0.45, while its current stock price of $33.32 trades below the average analyst target of $38.59.
Investors are primarily focused on the confirmation of the $950 million upfront cash payment from the Moderna patent settlement and the development timeline for the lead anti-FcRn asset, IMVT-1402.
Following the recent divestiture of Dermavant, the company has refocused its resources on late-stage clinical trials for brepocitinib and mosliciguat, which are expected to yield pivotal data in the second half of 2026.
With a cash runway bolstered by recent legal wins, management's guidance on capital allocation and potential share repurchases remains a key secondary interest for shareholders.